Endocannabinoid system components as potential biomarkers in psychiatry by Navarrete, Francisco et al.
Frontiers in Psychiatry | www.frontiersin.or
Edited by:
Helge Frieling,















This article was submitted to
Molecular Psychiatry,
a section of the journal
Frontiers in Psychiatry
Received: 15 January 2020
Accepted: 30 March 2020
Published: 27 April 2020
Citation:
Navarrete F, Garcı́a-Gutiérrez MS,
Jurado-Barba R, Rubio G,
Gasparyan A, Austrich-Olivares A







published: 27 April 2020
doi: 10.3389/fpsyt.2020.00315Endocannabinoid System
Components as Potential Biomarkers
in Psychiatry
Francisco Navarrete1,2, Marı́a Salud Garcı́a-Gutiérrez1,2, Rosa Jurado-Barba3,4,5,
Gabriel Rubio2,3,4,6, Ani Gasparyan1,2, Amaya Austrich-Olivares1
and Jorge Manzanares1,2*
1 Instituto de Neurociencias, Universidad Miguel Hernández-CSIC, Alicante, Spain, 2 Red Temática de Investigación
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The high heterogeneity of psychiatric disorders leads to a lack of diagnostic precision.
Therefore, the search of biomarkers is a fundamental aspect in psychiatry to reach a more
personalized medicine. The endocannabinoid system (ECS) has gained increasing interest
due to its involvement in many different functional processes in the brain, including the
regulation of emotions, motivation, and cognition. This article reviews the role of the main
components of the ECS as biomarkers in certain psychiatric disorders. Studies carried out
in rodents evaluating the effects of pharmacological and genetic manipulation of
cannabinoid receptors or endocannabinoids (eCBs) degrading enzymes were included.
Likewise, the ECS-related alterations occurring at the molecular level in animal models
reproducing some behavioral and/or neuropathological aspects of psychiatric disorders
were reviewed. Furthermore, clinical studies evaluating gene or protein alterations in post-
mortem brain tissue or in vivo blood, plasma, and cerebrospinal fluid (CSF) samples were
analyzed. Also, the results from neuroimaging studies using positron emission
tomography (PET) or functional magnetic resonance (fMRI) were included. This review
shows the close involvement of cannabinoid receptor 1 (CB1r) in stress regulation and the
development of mood disorders [anxiety, depression, bipolar disorder (BD)], in post-
traumatic stress disorder (PTSD), as well as in the etiopathogenesis of schizophrenia,
attention deficit hyperactivity disorder (ADHD), or eating disorders (i.e. anorexia and
bulimia nervosa). On the other hand, recent results reveal the potential therapeutic action
of the endocannabinoid tone manipulation by inhibition of eCBs degrading enzymes, as
well as by the modulation of cannabinoid receptor 2 (CB2r) activity on anxiolytic,
antidepressive, or antipsychotic associated effects. Further clinical research studies are
needed; however, current evidence suggests that the components of the ECS mayg April 2020 | Volume 11 | Article 3151
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Psychiatric disorders are one of the main causes of disability in
the general population (1). According to a recent estimation,
psychiatric disorders account for 32.4% of years lived with
disability (YLDs) and 13% of disability adjusted life-years
(DALYs), leading the global burden of disease (2). Despite this,
we still have a great lack of knowledge about its neurobiological
basis, and clinically applicable biomarkers have been elusive.
During the last decades, an increasing effort has been made in the
search of biomarkers in psychiatry to help in the diagnosis and
prediction of disease progression or treatment response.
However, a clinical biomarker should be validated, sensitive,
specific, feasible, and easily reproducible, characteristics that
make difficult the implementation in this field (3–5).stem; eCBs, endocannabinois; CB1r,
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g 2The endocannabinoid system (ECS) components (receptors,
ligands, synthesizing and degrading enzymes) have gained a
special interest because of their critical neuromodulatory
involvement in a plethora of functional mechanisms in the
central nervous system (CNS), including emotional regulation,
motivational behavior, and cognitive function (6, 7). The wide
distribution of ECS in the brain, together with the effects derived
from its pharmacological modulation on mood or cognition with
exogenous cannabinoid compounds, mainly those contained or
derived from the Cannabis sativa plant, suggests that the
identification of the functional role of ECS elements in certain
psychiatric disorders could be a breakthrough to improve
diagnosis and treatment (8–11).
Therefore, this review summarizes the findings regarding the
potential involvement of ECS components as biomarkers, mainly
in terms of the discovery of new therapeutic approaches, but also
from the point of view of its diagnostic, prognostic and predictive
application. For that purpose, studies on animal models and
patients have been collected focusing on the most prevalent
psychiatric conditions, including anxiety disorders (3.8%) (12),
depressive disorders (3.4%) (12), schizophrenia (0.3%) (12),
bipolar disorder (0.6%) (12), post-traumatic stress disorder
(7.8%) (13), attention-deficit hyperactivity disorder (2.2%)
(14), and eating disorders (0.2%) (12).A BRIEF OVERVIEW OF THE
ENDOCANNABINOID SYSTEM
COMPONENTS
ECS regulates a number of physiological functions and mediates
the crosstalk between different neurotransmitter systems,
therefore representing a key player in the control of behavioral
responses (15, 16). ECS is a ubiquitous lipid signaling system
distributed throughout the organism that participates in multiple
intracellular signaling pathways (17, 18). Cannabinoid receptors,
endogenous ligands or endocannabinoids (eCBs), and their
synthesizing and degrading enzymes are the main components
of the ECS (Figure 1) present in the central and peripheral
nervous system (15, 19) and in many other peripheral tissues
regulating distinct functions (20).
The CB1 receptor (CB1r) is the most abundant G protein-
coupled receptor in the brain (21). Physiological actions of
endocannabinoids in the CNS are mediated by the activation of
CB1r (22). Their expression in the CNS is widespread and
heterogeneous and has crucial roles regulating brain function and
disease processes (23–25). CB1r is abundant in the basal ganglia,
cerebellum, in corticolimbic regions including the prefrontal cortex
(PFC), nucleus accumbens (Nac), and hippocampus (Hipp), and inApril 2020 | Volume 11 | Article 315
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(Amy) and the paraventricular nucleus (PVN) of the hypothalamus
(Hyp) (21, 26, 27). Furthermore, CB1r is also located in terminals of
peripheral neurons and glial cells, as well as in the reproductive
system (i.e. uterus, ovary, testis, prostate), some glandular systems
(adrenal gland), adipose tissue, heart, liver, lung, bone marrow,
thymus, and the microcirculation (20, 26, 28–33).
CB2 cannabinoid receptor (CB2r) was initially considered as
a peripheral cannabinoid receptor due to its high expression in
the rat spleen (34) and leukocyte subpopulation in humans (32),
participating in the regulation of the immune system (35). The
first findings identified the presence of CB2r in the CNS only
under pathological conditions such as in senile plaques in
Alzheimer's disease (36), activated microglial cells/Frontiers in Psychiatry | www.frontiersin.org 3macrophages in multiple sclerosis, spinal cord in amyotrophic
lateral sclerosis (37) and in the vicinity of tumors (38). However,
Van Sickle and colleagues revealed that CB2r is expressed in
neurons of the brainstem of mice, rats, and ferrets under normal
conditions (39). This finding was key to increase the interest of
CB2r in the regulation of brain function. Different studies
identified CB2r in several brain regions including the frontal
cortex, striatum, basal ganglia, Amy, Hipp, and the ventral
tegmental area (VTA) (40–44). Interestingly, in some of these
brain regions, CB2r was detected not only in the microglia (45)
but also in the neurons (44, 46, 47).
The eCBs are lipid messengers acting as paracrine, autocrine, and
probably endocrine mode, because their lipid nature allows them to
diffuse and cross membranes (15, 17, 18, 48, 49). eCBs are agonists ofFIGURE 1 | Schematic representation of the main ECS components, including the metabolizing routes of the eCBs. CB1/CB2, cannabinoid receptors 1 and 2; 2-
AG, 2-arachidonoylglycerol; FAAH, fatty acid amide hydrolase; MAGL, monoacylglycerol lipase; DAGL, EMT: endocannabinoid membrane transporter; NAT, N-acyl
transferase; NArPE, N-arachidonoyl phosphatidylethanolamine; NAPE-PLD, N-acylphosphatidylethanolamine specific phospholipase D; DAGL, diacylglycerol lipase.
Image created with BioRender.April 2020 | Volume 11 | Article 315
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rather synthesized under tonic or phasic (on demand) modes, and
released to the extracellular space following physiological and
pathological stimuli (50). The two main eCBs are derivatives of
polyunsatured fatty acids, N-arachidonoylethanolamine
(anandamide, AEA) (51), and 2-arachidonoylglycerol (2-AG), being
the most abundant eCBs in the brain (52). Firstly, AEA synthesis is
produced by the N-acylphosphatidylethanolamine specific
phospholipase D (NAPE-PLD) that hydrolyzes N-arachidonoyl
phosphatidylethanolamine localized in cell membranes (49, 53).
The AEA half-life is very short because of its quick uptake by a
high affinity AEA membrane transporter distributed in the neurons
and glia (54). AEA is inactivated by fatty acid amide hydrolase
(FAAH) present in many organs and in the brain at postsynaptic
location (55, 56). FAAH is a serine-hydrolase enzyme bound to
intracellular membranes that metabolizes AEA into arachidonic acid
and ethanolamine (57). Secondly, 2-AG participates in the CB1r-
dependent retrograde signaling and is an intermediate metabolite for
lipid synthesis providing arachidonic acid for prostaglandin synthesis
(57). Neuronal membrane depolarization or the activation of Gq
protein-coupled receptors (GPCRs) triggers the synthesis of 2-AG
(49). The diacylglycerol precursors come from the hydrolysis of
membrane phosphatidylinositol by phospholipase C, b or d. The
degradation of these precursors by diacylglycerol lipases (DAGL-a
and DAGL-b) drives 2-AG synthesis (58, 59). The DAGLa isoform
synthesizes the greatest amount of 2-AG, whereas DAGLb
synthesizes 2-AG under certain circumstances (54).
Monoacylglycerol lipase (MAGL) is a serine-hydrolase enzyme
mainly found in presynaptic terminals that catalyzes 2-AG into
arachidonic acid and glycerol (55, 60). Also, the a/b-hydrolase
domain 6 (ABHD6) and domain 12 (ABHD12) degrade 2-AG
(49, 57).THE ENDOCANNABINOID SYSTEM IN
PSYCHIATRY: SEARCHING FOR
POTENTIAL BIOMARKERS
The ECS is one of the most widely distributed neurotransmitter
systems in the human brain, with a critical neuromodulatory role
that motivates the interaction with other neurotransmitter and
neurohormonal systems (61). Accumulating evidence points out
the pivotal role of the ECS in the regulation of cognitive and
behavioral functioning, suggesting its therapeutic potential in
psychiatry (9, 11, 62). Furthermore, it is worth to mention that
psychiatric disorders are accompanied by disturbances in the
ECS components, as detailed below. Taken together, these facts
suggest the potential usefulness of cannabinoid receptors,
endocannabinoid ligands and degrading or synthesizing
enzymes as biomarkers to move towards improved diagnostic
criteria and therapeutic approaches in psychiatry.
The literature review consisted of an exhaustive search for
scientific information in the Medline database (PubMed), which
was always focused on the following ECS components as
potential biomarkers in psychiatry: CB1r, CB2r, AEA, 2-AG,
FAAH and MAGL. A total of seven search boxes were employedFrontiers in Psychiatry | www.frontiersin.org 4according to the total of psychiatric conditions included in the
review: anxiety, depression, schizophrenia, bipolar disorder,
post-traumatic stress disorder, attention-deficit and
hyperactivity disorder, and eating disorders. These terms were
combined with the term ‘cannabinoid’ by the Boolean operator
‘AND’. All the results for each search were critically analyzed by
the authors to decide the inclusion or exclusion of each reference
according to the adequacy of its content with the subject matter
of the study. Finally, no PubMed filters were applied to maximize
the selection of all the available and appropriate information.
Anxiety Disorders
According to the Diagnostic and Statistical Manual of Mental
Disorders (DSM-5), anxiety disorders share features of excessive
fear and anxiety and related behavioral disturbances. Fear is the
emotional response to real or perceived imminent threat,
whereas anxiety is an emotional anticipatory response to future
potential threatening or stressful situations, triggering symptoms
of negative affective, somatic, behavioral and cognitive
components (63). The ECS plays a prominent role in the stress
response and anxiety, as it is widely documented mainly by
animal studies (64–67). However, our knowledge on the precise
molecular mechanisms of the ECS signaling in humans is
insufficient (68, 69). In the last years, compelling evidence for
the involvement of ECS in anxiety has been accumulated that
suggests new therapeutic leads through the discovery of
potential biomarkers.
Animal Studies
A large body of literature supports the involvement of CB1r as a
potential biomarker in anxiety disorders (70–72). CB1r is widely
distributed in brain areas associated with emotional regulation
and stress responsiveness such as PFC, Hipp, Amy, and Hyp
(19). Previous pharmacological studies evaluated the effects of
different cannabinoid compounds after either systemic or
intracerebral administration in rodents exposed to several
animal models of anxiety (73, 74). In addition, it is important
to highlight the pivotal role of CB1r in the effects of anxiolytic
drugs such as benzodiazepines. Indeed, our group demonstrated
that the CB1r antagonist, AM251, completely abolished the
anxiolytic effects and significantly reduced the amnesic and the
sedative actions induced by alprazolam (75). A very similar result
was recently obtained regarding the AM251-induced blockade of
the anxiolytic effects of alprazolam (76). On the other hand, the
enhancement of CB1r-mediated endocannabinoid function
increases the anxiolytic action of diazepam (77).
Accumulated evidence points out that CB1r manipulation
produces a bidirectional effect on anxiety-related behavior (78,
79). CB1r activation decreases anxiety at lower doses (80),
whereas anxiogenic effects occur at higher doses or after CB1r
blockade (70, 81–87). However, several factors could modify this
general assumption such as regional endogenous tone, age, sex,
species differences, type of test, previous exposure to stressful
situations, or dosage of cannabinoid receptor agonists or
antagonists. In addition, the underlying mechanisms involved
in the bidirectional effects of CB1r pharmacological modulation
remain poorly understood. Among the available evidencesApril 2020 | Volume 11 | Article 315
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cortical glutamatergic neurons mediates the anxiolytic effect of
CP-55,940 cannabinoid agonist at low doses, whereas anxiogenic
actions of higher doses are related with CB1r and GABAB
receptors in GABAergic terminals (88). A growing body of
evidence also suggests that the anxiogenic effects of moderate
to high cannabinoid doses appear to be mediated by the
interaction between endocannabinoid and endovanilloid
systems, specifically through the activation of transient
receptor potential cation channel subfamily V member 1
(TRPV1) vanilloid receptors (89). In this regard, the
combination of high WIN-55,212 doses in the dorsolateral
periaqueductal gray matter (dlPAG) with the TRPV1
antagonist capsazepine abolished the anxiogenic effect (90).
Furthermore, the anxiolytic effects of high doses of the
cannabinoid agonist ACEA combined with an antagonist of
TRPV1 in the rat prelimbic medial prefrontal cortex (PL)
suggested the critical interaction between both systems (91).
Moreover, the co-administration of intra-dlPAG AEA at higher
doses with a nitric oxide (NO) scavenger (carboxy-PTIO)
restored the anxiolytic profile, leading to the hypothesis that
the increase in anxiety-like behavior mediated by TRPV1
receptors is due to subsequent NO formation (92).
Deletion of CNR1 gene in mice (CB1−/− mice) has been
another important tool to elucidate the role of this
cannabinoid receptor in anxiety. Many studies have
demonstrated the clear anxiety-like behavior of male CB1−/−
mice (70–72, 83, 93, 94), although there are some negative results
(95). Among the multiple mechanisms involved in the anxious
phenotype shown by CB1−/− mice, significant age-dependent
alterations in the metabolism of endocannabinoids could be
pointed out (96). Interestingly, CB1−/− female mice do not
have an anxious phenotype in comparison with female wild-
type (WT) subjects. This finding supports an interaction between
sex and the ECS at early stages of development that is critical for
establishing adult anxiety-like behavior (97). Indeed, these sex-
specific effects were also described under pharmacological
blockade of CB1r (98). Furthermore, our group described that
the effects of the anxiolytic drugs bromazepam and buspirone
were missing in CB1−/− mice (99), suggesting a critical role of
CB1r that was related with the control of GABAergic responses
mediated by GABAA and GABAB receptors (100).
Recent studies provide relevant information regarding the
specific brain regional involvement of CB1r-mediated anxiolytic
actions. In this sense, the intra-dlPAG administration of AEA,
ACEA (selective CB1r agonist) or AM404 (AEA reuptake
inhibitor) induced anxiety-like responses that were blocked by
AM251 (CB1r antagonist) (101). Similarly, AEA-mediated CB1r
activation produces anxiolytic-like actions in the dlPAG
employing a panic-like animal model (102, 103) or the Vogel
conflict test (104). In addition, facilitation of 2-AG-mediated
signaling in the dorsomedial hypothalamus (DMH) significantly
reduced panic-like responses in Wistar rats, an effect that was
reversed by the CB1r antagonist AM251 (105). Furthermore,
activation of CB1r by 2-AG in the basolateral amygdala (BLA)
has a critical role in the effects of stress-induced glucocorticoidFrontiers in Psychiatry | www.frontiersin.org 5release on suppression of synaptic GABAergic inhibition (106).
Interestingly, pharmacologically-induced elevations of AEA or 2-
AG in the BLA decrease anxiety in the elevated plus maze (EPM)
test under conditions of low emotional arousal while are
ineffective when the level of emotional arousal increased (107).
Moreover, electron microscopy revealed CB1r expression in the
rat lateral habenula (LHb), mediating the actions of increased 2-
AG levels after acute stress exposure, while its blockade by
SR141716 (rimonabant) significantly reduced anxiety-like
behavior (108). In another study, WIN-55,212 was locally
administered in the lateral septum (LS) of male Wistar rats,
producing a CB1r-mediated anxiogenic response in the EPM
paradigm since AM251 blocked this effect (109). Also, the role of
CB1r functional manipulation in anxiety behavior regulation and
the effects on subsequent signaling pathways in relevant
corticolimbic areas such as PFC, AMY, NAc, and Hipp (110–
116) have been evaluated.
A better understanding of the functional connections of the
ECS with other neurotransmitter or neurohormonal systems is
relevant to understand the role of ECS components as potential
biomarkers in psychiatry. According to previous studies, CB1r is
located in the locus coeruleus (LC) and in the dorsal raphe
nucleus (DRN), and it regulates noradrenaline (NA) and
serotonin (5HT) release, respectively, by the modulation of
GABAergic and glutamatergic terminals (117, 118). In
addition, the dopaminergic and opiodergic systems of the Amy
may also be involved in the anxiolytic-like effects induced by the
activation of CB1r (119, 120). Furthermore, the involvement of
the ECS in the regulation of the hypothalamus–pituitary–adrenal
(HPA) axis after stress exposure attracted special attention in the
last years (121). Gray and cols. recently found that the stress-
related neuropeptide corticotropin-releasing hormone (CRH),
acting through the CRH type 1 receptor (CRHR1), reduces AEA
levels in the PFC and the Amy by increasing the hydrolysis of
FAAH and by increasing 2-AG levels. These data suggest that
stress-related elevations in CRH signaling induce persistent
changes in eCB function, impairing its tonic regulation on
stress and enhancing anxiety responses (122, 123).
Genetic studies pointed out interesting results regarding the
involvement of polymorphisms or epigenetic modifications of
CNR1 as susceptibility/risk biomarkers to develop anxiety
disorders. Lazary and cols. analyzed the interaction of the
promoter regions of the serotonin transporter (5HTT;
SLC6A4) and CNR1 genes on anxiety. Specific constellations of
CB1r and 5HTT promoters were closely associated with high or
low synaptic 5HT concentrations, which could result critically in
the vulnerability to experience an anxiety disorder (124). Hay
and cols. employed CRISPR/CAS9 technology to disrupt a highly
conserved regulatory sequence (ECR1) of the gene encoding
CB1r (CNR1). This manipulation significantly reduced CNR1
expression in the Hipp, but not in the Hyp, and induced a sex-
dependent anxiogenic effect (125). In addition, a connection
between ECS and epigenetic mechanisms was proposed. The
exposure to immobilization stress increases anxiety-like
behavior, an effect blocked by histone deacetylase (HDAC)
inhibitors. Interestingly, the CB1r antagonist rimonabantApril 2020 | Volume 11 | Article 315
Navarrete et al. Endocannabinoid System Biomarkers in Psychiatryattenuated the anxiolytic-like effects of the HDAC inhibitors,
suggesting an association between epigenetic mechanisms and
ECS signaling (126). Furthermore, in mice exposed to a chronic
unpredictable stress (CUS) there were reduced levels of histone
H3K9 acetylation (H3K9ac) associated with CB1r encoding
gene (127).
Since the direct pharmacological modulation of CB1r has
provided some disappointing results, in recent years much
attention has been paid to the therapeutic role of functional
manipulation of the endogenous cannabinoid ligands AEA and 2-
AG by inhibiting enzymatic degradation (FAAH and MAGL,
respectively) or blocking reuptake (128–132). AEA plays a crucial
role in emotional control (133). Inhibition of its degradation by
FAAH or its reuptake induces a robust anxiolytic effect (134–142).
Indeed, stress exposure induces anxiety-like behavior and reduces
AEA brain levels (143) by increasing FAAH activity in the Amy
(144), a brain region closely involved in AEA-mediated emotional
regulation (145). According to the effects observed in FAAH
knockout mice (FAAH−/− mice), as well as with the
administration of URB597 (FAAH inhibitor), preservation of
CB1r function regulating GABA transmission in the striatum may
be one the mechanisms involved in the anxiolytic actions of FAAH
inhibition (146, 147). Environmental experimental conditions are
critical to observe the anxiolytic effect of FAAH inhibition, only
present under high stressful or aversive stimuli (148). Interestingly,
the dual blockade of FAAH and TRPV1 represents another
therapeutic approach to reduce anxiogenic behavior (149). In
addition, co-administration of an ineffective dose of URB597 with
an ineffective dose of diazepam led to a synergistic anxiolytic
action (77).
The endocannabinoid 2-AG also presents a close involvement in
emotional regulation linked with signaling in hippocampal
glutamatergic neurons (150). In the last years, several evidences
support the anxiolytic actions associated with the inhibition of 2-AG
enzymatic degradation by means of MAGL (151–153). A link with
the HPA axis has been proposed, since the elevation of 2-AG levels
was accompanied by a dramatic increase in plasma corticosterone,
effect that is probably mediating its anxiolytic actions (154). In
addition, increased 2-AG levels in the NAc of mice previously
exposed to chronic social defeat stress are associated with an
anxiolytic effect and the enhancement of synaptic plasticity (155).
Furthermore, the enhancement of 2-AG levels in the dlPAG by the
local injection of 2-AG or the hydrolysis inhibitor, URB602,
prevented NMDA-induced panic-like response in Wistar rats
(156). Interestingly, genetic deletion of MAGL in mice induced an
anxiety-like phenotype (157), whereas mice lacking DAGLa
showed a high anxiety-like phenotype, strengthening the critical
involvement of 2-AG in emotional regulation (158, 159).
Another relevant endocannabinoid biomarker is the CB2r.
The first studies demonstrating the role of this receptor in the
regulation of anxiety-like behavior were performed in our
laboratory employing transgenic animals overexpressing CB2r
in the brain (CB2xP mice). Increased expression of CB2r was
significantly correlated with reduced anxiogenic-related
behaviors. Interestingly, CB2xP mice presented an impaired
HPA-axis response to restraint stress, as well as increasedFrontiers in Psychiatry | www.frontiersin.org 6GABAAa2 and GABAAg2 gene expression probably accounting
for the lack of anxiolytic action of alprazolam in these animals
(160). Furthermore, a pharmacological approach to evaluate
acute and chronic effects of the activation (JWH133, CB2r
selective agonist) or blockade (AM630, CB2r selective
antagonist) of CB2r revealed opposite effects. Importantly,
chronic CB2r blockade induced a significant anxiolytic effect
that was associated with an upregulation of CB2r, GABAAa2 and
GABAAg2 in the cortex and the amygdala (160). In line with these
results, the acute activation of CB2r by the administration of b-
caryophyllene (BCP) induced an anxiolytic effect that was
completely abolished by AM630-mediated CB2r blockade
(161). Recently, Robertson and cols. described that CB2r gene
expression is rapidly increased in the Hipp after social stress
exposure (social defeat) (162). Genetic manipulation
experiments allowed the deepening in the cell-specific
functional involvement of CB2r in the Hipp, dissecting the
effects of CB2r gene expression disruption in hippocampal
neurons or microglia on the regulation of anxiety behavior
(163). Moreover, the functional role of CB2r in VTA
dopaminergic neurons was also explored. Surprisingly, deletion
of CNR2 in VTA dopaminergic neurons induced a very
significant anxiolytic effect (47).
Human Studies
In 1981, Fabre and McLendon published the first evidences
regarding the anxiolytic properties of cannabinoid compounds. In
this study, the synthetic cannabinoid nabilone was administered to
25 patients, producing a significant improvement in anxiety (164).
Nowadays, there is a large body of evidence regarding cannabis
consumption and regulation of anxiety behavior (165), although the
underlying mechanisms are poorly understood. A recent study
addressed this issue by combining fMRI and positron emission
tomography (PET) in 14 patients following an oral dose of delta-9-
tetrahydrocannabinol (THC) while they were performing a fear-
processing task. The results suggested that the acute effects of
cannabis on anxiety in males are mediated by the modulation of
amygdalar function by THC and the extent of these effects are
related to local availability of CB1r (166). On the other hand, several
clinical trials using rimonabant to treat obesity showed psychiatric
side effects such as increased anxiety behavior, depression or even
suicidality (167). In spite of the presence of important confounding
factors that probably were not appropriately taken into
consideration (e.g. psychiatric comorbidity in obese patients),
rimonabant was withdrawn from the market, and the enthusiasm
in its therapeutic usefulness significantly decreased. Interestingly, a
recent report suggested that rimonabant increases anxiety only
under an aversive/anxiogenic situation (public speaking), without
modifying baseline anxiety behavior (168). Alternative
pharmacological approaches to modulate CB1r are now under
investigation. Neutral antagonists, peripherally restricted ligands,
and allosteric modulators may provide promising results [for a
recent review (169)].
The elucidation of genetic variations of different
endocannabinoid components involved in the vulnerability to
develop anxiety-related disorders has recently gained greatApril 2020 | Volume 11 | Article 315
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between four categories of stressful life events and specific
genetic variations in the CNR1 rs7766029 polymorphism, for
the development of depression and anxiety. The results suggested
that CNR1 rs7766029 interacted significantly with financial but
not with other types of life events to increase the vulnerability to
develop depression and anxiety (170). In addition, allelic variants
of the gene encoding FAAH have been involved in the regulation
of anxiety-related behaviors. First, the disturbances of FAAH
genetic variation in AEA hydrolysis appear related with
alterations in frontolimbic circuits (171), with an age-
dependent effect accounting for differences between the
adolescence and childhood life stages (172). Second, an
interaction between genetic variations of FAAH and
corticotropin-releasing hormone receptor type 1 (CRHR1) has
been described in relation with the risk to develop anxiety
disorders (173, 174). Third, reduced FAAH activity in patients
carrying the A allele of the FAAH rs324420 (C385A)
polymorphism significantly increases the vulnerability to
develop anxiety and depression when exposed to repetitive
childhood trauma (175). Moreover, a functional variant of
gene encoding CB2r (Cnr2) appears to interact with FAAH
gene, increasing the sensitivity for childhood trauma when
both are dysfunctional (176).
Depressive Disorders
Major depressive disorder (MDD) has been one of the leading
causes of years lived with disability (YLD) during the last three
decades (1). According to the World Health Organization
estimation for 2015, the number of people living with
depression in the world is 322 million, and it is a major
contributor to suicide deaths (177). DSM-5 states that the
common feature of depressive disorders is the presence of sad,
empty, or irritable mood, accompanied by somatic and cognitive
changes that significantly affect the individual's capacity to
function. MDD is being characterized by distinct changes in
affect, cognition, and neurovegetative functions with episodes
lasting for at least 2 weeks. Additionally, five or more symptoms
have to be present during the same episode, with at least one of
the symptoms being either depressed mood or anhedonia (63).
Nowadays, pharmacological treatment of MDD entails relevant
limitations such as delayed onset of antidepressive actions and
appearance of important side effects. The limited success of drug
discovery in the context of depression is ultimately linked to an
inadequate understanding of the underlying biology of this
disorder. In this sense, there is evidence to suggest that the
ECS is impaired in MDD providing a unique opportunity to
identify potential diagnostic and therapeutic biomarkers.
Animal Studies
Martin and cols. employed the CB1−/− mice and exposed them to
the CUS procedure. Their findings showed that CB1−/− were
more vulnerable to CUS-induced depressive-like responses and
presented an increase susceptibility to develop anhedonia (94).
Some years later, it was shown that the increased despair
behavior in CB1−/− mice was critically associated with down-Frontiers in Psychiatry | www.frontiersin.org 7regulated brain-derived neurotrophic factor (BDNF) levels in the
Hipp. Also, local administration of BDNF in the Hipp of these
animals reversed the depressive-like phenotype (178). A
complete genetic screening by mRNA microarray hybridization
revealed a differential gene expression pattern related to the high
depressive-like behavior of CB1−/− mice at basal conditions
(179). According to the results derived from the studies
employing CB1−/− mice, it was proposed that CB1−/− mice
could represent a validated and appropriated model to evaluate
depressive-like disorders (180).
In the tail suspension test (TST) and forced swimming test
(FST), acute AM251 injection induced an antidepressant effect,
decreasing the immobility time in both behavioral paradigms
(181). Similar results were obtained by both the acute and
chronic administration of rimonabant in Wistar rats and
BALB/c mice employing the FST and the chronic mild stress
(CMS) paradigms, respectively (182). However, other results
reveal that the activation of CB1r mediates antidepressant
effects (183–187), and even that chronic rimonabant
administration produces a depressogenic effect (188).
Interestingly, McLaughlin and cols. showed that CB1r located
in the dentate gyrus of the Hipp was responsible for the
antidepressant effects of the CB1r agonist HU-210 (189). In
addition, a very recent study elegantly discovered a circuit-
specific CB1r-mediated modulation of glutamatergic
transmission that shapes the information flow from BLA to the
NAc (190). In this study, the authors consider if the reduction of
CB1r in the NAc may be used as a biomarker for MDD diagnosis
and point out that this aspect needs to be further determined by
evaluation of CB1r levels in the NAc of MDD patients (190).
The evaluation of ECS components disturbances in animal
models of depressive disorders provided relevant information.
Hill and cols. showed that male Long–Evans rats exposed to the
CUS presented increased CB1r binding site density in the PFC
while decreased in the Hipp, Hyp and Nac, and lower levels of
AEA were found in all these brain regions (191). Furthermore,
sex-dependent effects of CUS were analyzed in Sprague-Dawley
rats, obtaining lower and higher CB1r protein expression in
males and females, respectively, whereas increased FAAH levels
were present in both sexes (192). In addition, further studies
employing the CUS procedure specifically focused on CB1r-
mediated signaling, revealing significant loss of function
disturbances in the NAc (193) and in the LHb (194).
Moreover, apart from stress-related animal models, Flinders
Sensitive Line (FSL) or Wistar Kyoto (WKY) rats are well-
known genetic rat models of depression that were recently
used to exhaustively analyze disturbances in different
components of the ECS in specific brain regions and plasma
(195, 196).
Enhancement of endocannabinoid signaling has been
postulated as a new promising pharmacological strategy in the
treatment of stress-related disorders (e.g. anxiety or depression)
(197). Accordingly, a significant reduction in depressive-like
behavior was found after the administration of the FAAH
inhibitors URB597 (196, 198, 199) or PF3845 (200). In
addition, the inhibition of MAGL by the administration ofApril 2020 | Volume 11 | Article 315
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animal model of depression. Interestingly, JZL194-mediated
effects may be related with an enhancement of adult
neurogenesis and long-term synaptic plasticity in the dentate
gyrus of the Hipp, probably activating mTOR signaling pathway
(201). Furthermore, a recent study evaluated the effects of
JZL195, a dual inhibitor of FAAH and MAGL, in WKY rats.
JZL195 elevated the endocannabinoids and BDNF levels in the
ventral striatum and reduced the depressive-like phenotype in
female WKY rats (202).
In spite of the limited available results, CB2r is also critically
involved in emotional regulation (203). Probably, the first evidence
suggesting the role of CB2r in depression was a significant reduction
of these receptors in the striatum, midbrain, and Hipp in an animal
model of depression (204). Afterwards, a study showed the
antidepressant effects of the CB2r-seletive agonist GW405833 in
rats (205). Interestingly, our group further evaluated CB2r
involvement in depressive-like behavior regulation using genetic
and pharmacological approaches. Mice overexpressing CB2r
(CB2xP) presented decreased depressive-like behaviors under
basal conditions or after the exposure to a CUS procedure. In
addition, the chronic administration of AM630 blocked the CUS-
induced depressogenic effect in stressed mice, effect associated with
an upregulation of CB2r and BDNF in the Hipp (43). Recently,
similar results were obtained by CB2r functional activation through
the administration of the CB2r agonists JWH133 (206) and b-
caryophyllene (207). Furthermore, the specific deletion of CB2r in
midbrain DA neurons in DAT-Cnr2 conditional knockout (cKO)
mice significantly increased depressive-like behavior (47).
Crosstalk of ECS with other neurotransmitter or neurohormonal
systems plays a pivotal role in the effects produced by antidepressant
drugs. In this regard, interactions with the serotonergic system
represent a critical point due to the widely recognized clinical
therapeutic usefulness of antidepressants targeting serotonin (e.g.
serotonin selective reuptake inhibitors, SSRIs). SSRIs fluoxetine and
escitalopram modify the concentrations of different ECS
components under basal conditions (208–210) or in an animal
model of depression (211). Furthermore, low doses of WIN-55,212
produced antidepressant-like actions that appeared to be mediated
by 5HT (212), and CB1−/− mice have decreased levels of 5HT
transporter (5HTT) (213). Moreover, co-administration of a
subeffective dose of fluoxetine potentiated the effect of subeffective
doses of AEA, AM404 or URB597 (214). In addition, ECS also
interacts with other systems involved in emotional and stress
regulation such as the HPA axis (215), glutamatergic (216),
opioidergic (217), and cholinergic (218) systems.
On the other hand, it is relevant to highlight that
nonpharmacological approaches such as repeated transcranial
magnetic stimulation (rTMS) improve depressive-like behavior, at
least in part, by modulating the ECS. Recent studies performed in
rodents exposed to CUS and subsequently treated with rTMS
revealed that: 1) rTMS increases BDNF production and
hippocampal cell proliferation to protect against CUS-induced
changes through its effect on CB1r (219); 2) rTMS antidepressive
effects are at least partly mediated by increasing hippocampal 2-AG
and CB1 receptor expression levels (220); and 3) high-frequencyFrontiers in Psychiatry | www.frontiersin.org 8rTMS induces its antidepressant effect by upregulating DAGLa and
CB1r (221). In addition, electroconvulsive therapy (ECT)
significantly reduced AEA content and FAAH activity in the PFC
of Sprague-Dawley rats, as well as decreased and enhanced binding
site density of the CB1r in the PFC and Amy, respectively (222).
Human Studies
Besides the preclinical clues supporting the critical role of ECS in
depression, currently there is a broad body of evidence available
from clinical studies. Among them, those evaluating alterations
in different ECS components in post-mortem brain tissue or
plasma samples have provided compelling results. The first
evidence revealed that CB1r protein expression was decreased
in the anterior cingulate cortex (ACC) of patients with major
depression (223). Furthermore, Choi and cols. showed that CB1r
mRNA levels were higher in the PFC of major depression
patients (224). However, in a recent study a lack of CB1r
protein expression differences was found between depressive
subjects and paired control patients (225).
In the last years, an increasing effort has been made to elucidate
the alterations of ECS components (mainly the endocannabinoids
AEA and 2-AG) in blood samples of patients with depression, to
identify possible trait, prognosis or monitoring biomarkers that
could improve the therapeutic approach. In a cohort of 28 women
with diagnostic criteria for clinical depression and without
medication, serum 2-AG content was significantly decreased, and
this decrease was negatively correlated with duration of the
depressive episode (226). Similarly, basal serum concentrations of
AEA and 2-AG were significantly lower in women with nontreated
major depression, and the exposure to a stressful situation
significantly increased 2-AG concentrations without modifying
AEA (227). However, another study described increased plasma
concentrations of both AEA and 2-AG in depressed patients, and
the elevation of 2-AG was significantly associated with SSRI
antidepressant therapy (228). Interestingly, the antidepressant-
related effects or physical exercise on eCBs levels were also
analyzed. Intense exercise in control healthy patients induced a
significant increase in AEA serum levels that was correlated with
higher BDNF levels, whereas 2-AG concentrations remained stable
(229). On the contrary, moderate exercise in women with MDD
produced significant elevations in AEA but not in 2-AG, although
both eCBs presented significant moderate negative associations
between serum changes and mood states (230). Finally, ECT
significantly elevated AEA and 2-AG levels in the cerebrospinal
fluid (CSF) of patients with major depression (231).
The ECS-related polymorphic gene variant study results are
relevant because of the potential diagnostic and therapeutic
implications. Regarding the CNR1 and the single nucleotide
polymorphism (SNP) rs1049353 (G1359A) that may contribute
to the susceptibility to mood disorders (232), G-allele has been
associated with higher depressive-related symptomatology (233)
and increased risk of antidepressant treatment resistance in
women with comorbid anxiety disorder (234). However, it
provides a better response to citalopram in male depressive
patients (235), whereas A-allele decreased risk to develop
depression because of childhood physical abuse (236).April 2020 | Volume 11 | Article 315
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related with high neuroticism and low agreeableness
personality traits, increasing the risk to develop depression
(237). On the other hand, the presence of 2 long alleles of the
polymorphic triplet (AAT)n of CNR1 gene was associated with
reduced prevalence of depression in Parkinson's disease patients
(238). In addition, the minor C allele of the CNR1 rs2023239
polymorphism may confer a protective effect against lifetime
development of MDD in methadone-maintained patients (239).
Despite the previous findings, a recent meta-analysis points out
that CNR1 rs1049353 or AAT triplet repeat polymorphism had
no association with susceptibility to depression (240).
Other relevant gene polymorphisms of the ECS are those
related with FAAH and CB2r. First, variants of the FAAH gene
may be related with susceptibility to mood disorders such as
major depression (232). In fact, genetically reduced FAAH
activity in A allele carriers of FAAH rs324420 (C385A)
polymorphism constitutes a risk factor to develop anxiety and
depression in patients exposed to repetitive childhood trauma.
Interestingly, the authors noted that this genotype could entail
pharmacogenomic consequences, namely ineffectiveness or
adverse effects of FAAH inhibitors in this subpopulation (175).
Second, polymorphisms of CNR2 were first studied by Onaivi
and cols. in Japanese depressed patients, revealing a high
incidence of Q63R but not H316Y polymorphism (204, 241).
Recently, the R allele of Q63R CNR2 polymorphism, together
with the A allele of FAAH C385A polymorphism were associated
with increased sensitivity for childhood trauma and subsequent
expression of anxious and depressive phenotypes (176). Finally,
according to the previously mentioned recent meta-analysis
performed by Kong and cols., CNR2 rs2501432 polymorphism
might be closely associated with depression (240).
Schizophrenia
According to the DMS-5 schizophrenia is a psychotic disorder
associated with a myriad of signs including positive symptoms
(delusion, hallucinations, disorganized speech or grossly
disorganized or catatonic behavior), negative symptoms (lack
of motivation and social withdrawal), and cognitive symptoms
(reduced attention and altered speech) (63, 242, 243). An
extensive body of literature supports the role of ECS in
schizophrenia neuropathology, a fact that is mainly sustained
by the psychotic effects derived from cannabis consumption and
attributed to the exogenous cannabinoid THC (244). Therefore,
a great interest has been posed in the identification of specific
biomarkers related with ECS functioning for preventive,
diagnostic, or therapeutic purposes.
Animal Models
Preclinical research that focused on the role of ECS in
schizophrenia relies on the evaluation of sensorimotor gating
deficits by the prepulse inhibition (PPI) paradigm (245, 246).
Among all the components of the ECS, CB1r is critically involved
in schizophrenia. In fact, results of studies using pharmacological
approaches showed that CB1r activation induces psychotic-like
effects, while blockade of CB1r presents opposite actions.Frontiers in Psychiatry | www.frontiersin.org 9Decreases in startle responses together with PPI disruption
were achieved by CP-55,940 administration, and rimonabant
completely reversed these effects (247). A similar experiment was
carried out in which CP-55,940 decreased startle response and
impaired PPI, and rimonabant significantly reversed CP-55,940-
induced deficits in PPI only at the lower prepulse intensity (248).
This CB1r-mediated auditory gating disruption was further
confirmed by measuring neuronal network oscillations in the
Hipp and entorhinal cortex of Sprague-Dawley rats. CP-55,940
significantly impaired sensory gating and neuronal oscillation, an
effect that was reversed by AM251 (249).
After learning that the modulation of the CB1r produced
sensorimotor alterations, different animal models of schizophrenia
were used to find out if CB1r blockade could be a strategy with
therapeutic potential. Blockade of N-methyl-D-aspartate (NMDA)
receptors (NMDAr) was used to simulate schizophrenia-like
symptoms in rodents (250). Interestingly, the administration of
AM251 significantly abolished phencyclidine-induced disruption of
PPI in a similar way to clozapine (251), as well as impairments in
recognition memory or increased behavioral despair in the FST
(252). Another NMDAr antagonist used to model schizophrenia-
like behavior is MK-801. The administration of the CB1r antagonist
AVE1625 reversed MK801-induced cognitive impairments and
decreased catalepsy and weight gain induced by clinically used
antipsychotic drugs (haloperidol, olanzapine) (253). Furthermore,
AM251 attenuated amnesic effects and hyperactivity induced by
MK-801 (254). Therefore, it appears that blockade of CB1r may
have relevant therapeutic applications for the treatment
of schizophrenia.
In the so-called ‘three-hit' animal model of schizophrenia, CB1r
binding and cannabinoid agonist-mediated G-protein activation
decreases in the cortical, subcortical, and cerebellar brain regions
(255). In a neurodevelopmental animal model of schizophrenia
induced by the gestational administration of methylazoxymethanol
(MAM), CB1r mRNA levels were lower in the PFC and higher in
the dorsolateral striatum of adult MAM-treated Sprague-Dawley
rats relative to the control group (256). Moreover, in the
spontaneously hypertensive rat (SHR) strain, partially reproducing
some schizophrenia-like behavioral aspects, CB1r immunoreactivity
was significantly increased in the PL, cingulate cortex, and CA3
region of the Hipp (257). Recently, two studies found decreased
methylation of the cannabinoid receptor interacting protein
(CNR1P1) DNA promoter in the ventral Hipp (vHipp) of rats
exposed to the MAMmodel (258, 259). CNR1P1 is an intracellular
protein that interacts with the C-terminal tail of CB1r and regulates
its intrinsic activity. Interestingly, a lentivirus-mediated
overexpression of CNR1P1 in the vHipp of Sprague-Dawley rats
induced significant schizophrenia-like cognitive and social
interaction impairments, together with an increase of dopamine
neuron population activity in the VTA (260).
Apart from the many preclinical studies supporting the
pivotal role of CB1r, animal models of schizophrenia provided
interesting results about eCBs brain level alterations. In this
regard, a significant increase in 2-AG levels in the PFC of PCP-
treated Lister-Hooded rats was reversed by treatment with THC,
which in turn induces a large reduction of AEA in the sameApril 2020 | Volume 11 | Article 315
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bilateral olfactory bulbectomy, considered as an animal model of
depression and schizophrenia, a significant decrease of AEA and
2-AG levels was found in the ventral striatum (262). In addition,
mice with a heterozygous deletion of neuregulin 1 (Nrg 1 HET
mice), a well-accepted and characterized animal model of
schizophrenia (263), displayed relevant alterations in eCBs
levels (264).
Finally, CB2r has also been recently involved in
schizophrenia. Ishiguro and cols. studied the effects of the
pharmacological blockade of CB2r in two animal models of
schizophrenia induced by the administration of MK-801 or
metamphetamine. The CB2r antagonist AM630 significantly
exacerbated the MK-801- or metamphetamine-induced
hyperlocomotion and PPI disruption, suggesting that CB2r was
mediating these actions (265). Our group analyzed exhaustively
the behavioral profile of CB2−/− mice to evaluate the implication
of CB2r in schizophrenia-like behavior. The phenotype showed
by CB2−/− mice resembled some relevant features of
schizophrenia such as increased sensitivity to motor effects of
cocaine, anxiety- and depressive-like behavior, disrupted short-
and long-term memory consolidation and impaired PPI. These
behavioral alterations were accompanied by gene expression
changes in different targets from dopaminergic, noradrenergic,
and serotonergic systems. Interestingly, the atypical
antipsychotic risperidone significantly improved PPI disruption
induced by CB2r deletion and differentially modulated some of
the neurochemical disturbances compared with WT mice (266).
In addition, the activation of CB2r by the agonist JWH015
reversed PPI disruptions of the MK-801-induced animal model
of schizophrenia, and this effect was specifically mediated by
CB2r since only AM630 but not AM251 abolished PPI
improvement (267). Furthermore, activation of CB2r
(JWH133) and blockade (AM630) increased MK-801-induced
hyperlocomotion, although this effect was much more evident
and pronounced with AM630 (268). Therefore, these results
strongly suggest that CB2r functional regulation is significantly
involved in schizophrenia-like behavior.
Human Studies
To date, an extensive and great effort has been made to elucidate
the role that CB1r plays in schizophrenia. Accumulated clinical
data clearly shows significant alterations of CB1r protein and
gene expression levels, as well as certain CNR1 polymorphisms
correlations, especially in the brain but also in the peripheral
blood cells from schizophrenic patients in comparison with
healthy control subjects. The information reviewed and
detailed below provides important clues to further investigate
the application of CB1r-related measures as potential trait, state,
prognostic or even therapeutic biomarkers.
Several published studies analyzed CB1r protein and gene
expression levels in different post-mortem brain regions from
schizophrenic patients. Several studies examined quantitative
autoradiography to evaluate CB1r availability through the
binding of different radioligands. A significant increase in CB1r
availability was shown in the dorsolateral prefrontal cortexFrontiers in Psychiatry | www.frontiersin.org 10(DLPFC) (269–271), although this increase was only present in
paranoid schizophrenic patients (272). Interestingly, a recent
study failed to show differences in CB1r-mediated functional
coupling to G-proteins in the PFC of schizophrenic and control
patients (273). Furthermore, higher CB1r binding levels were
shown in the left ACC (274) and in superficial layers of the
posterior cingulate cortex (PCC) (275), whereas no changes were
found in the superior temporal gyrus (STG) (276) from
schizophrenic patients. In contrast, some authors reported
lower CB1r protein levels measured by immunocytochemistry
(277) or Western blot (278) and decreased CB1r gene expression
analyzed by in situ hybridization (277) or quantitative real time
polymerase chain reaction (qRT-PCR) (273) in the PFC from
schizophrenic patients compared with control subjects. Volk and
cols. specifically addressed this apparent discrepancy between
CB1r binding and protein or gene expression levels. In a cohort
of 21 schizophrenic patients presenting lower levels of both CB1r
mRNA and protein in the PFC, relative to matched healthy
comparison subjects, they obtained an increased CB1r
binding (271).
Neuroimaging experiments were recently carried out to
obtain an in vivo approximation of the disturbances related
with CB1r in schizophrenia. In this regard, PET studies yielded
dissimilar results. Wong and cols. studied CB1r binding
employing the novel PET tracer [11C]-OMAR (JHU 75528) in
schizophrenic patients and matched controls. CB1r binding was
higher in several brain regions of patients with schizophrenia,
only reaching statistical significance in the pons. Interestingly, a
significant correlation was found between CB1r binding and
schizophrenia-related symptomatology (279). In addition,
Ceccarini and cols. also showed a significant increase of CB1r
binding in the NAc, insula, cingulate cortex, inferior frontal
cortex, parietal and mediotemporal lobes in schizophrenic
patients compared with controls measured with [18F]-MK-
9470 PET. It is relevant to highlight that in the nontreated
schizophrenia patients, CB1r binding was negatively correlated
to negative symptoms and to depression scores, especially in the
NAc (280). On the contrary, Rangathan and cols. obtained an
opposite result with lower CB1r availability levels ([11C]-OMAR
PET) in the Amy, caudate, PCC, Hipp, Hyp, and insula of
schizophrenic patients (281). An interesting commentary on
these discrepancies was published, in which several
confounding factors such as symptom severity, sex, age, PET
tracer, statistical analysis method or comorbid nicotine use are
discussed. Overall, it could be concluded that CB1r has an
important but yet complex and poorly understood role in
schizophrenia (282). Finally, a very recent study examined
CB1r availability by [18F]-FMPEP-d2 or [11C]-MePPEP PET,
in first episode psychosis (FEP). Significant lower CB1r
availability was found in patients with schizophrenia,
independently of antipsychotic medication treatment. Greater
reduction in CB1r availability was associated with greater
symptom severity and poorer cognitive functioning (283).
The possible association between CNR1 polymorphisms and
schizophrenia has been explored. In this sense, negative results
were obtained with a single-base polymorphism within the firstApril 2020 | Volume 11 | Article 315
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at codon 453 in the coding region of CNR1 (285–288), or other
CNR1 polymorphisms such as rs6454674 (287), AL136096 (287),
rs806368 (288, 289), rs806379 (288), rs806380 (288), rs806376
(289), and rs806366 (289). However, significant associations of
CNR1 polymorphisms rs7766029, rs806366, and rs1049353 were
described (290). Regarding (AAT)n triplet repeat in the
promoter region of the CNR1 gene, discrepant results were
reported since Tsai and cols. suggested that this polymorphism
was not directly involved in the pathogenesis of schizophrenia in
a Chinese population (291), whereas it was significantly
associated with the hebephrenic or disorganized subtype of
schizophrenia (285). Interestingly, some relevant associations
were identified between specific CNR1 polymorphisms and
therapeutic response. Hamdani and cols. described increase G-
allele frequency of the rs1049353 polymorphism in responsive
schizophrenic patients, with a dose effect of the G allele. Thus,
the authors proposed that the G allele of CNR1 rs1049353
polymorphism could represent a “psychopharmacogenetic”
biomarker to take into consideration for the treatment of
schizophrenia (288). In addition, in 65 FEP patients, TT
genotype of the CNR1 rs2023239 polymorphism was
associated with a better improvement of negative and positive
symptoms (292). Similarly, in another group of patients with
FEP, carriers of rs7766029 CC genotype presented significantly
higher improvement in verbal memory and attention while
carriers of rs12720071 AG genotype showed a better
improvement in executive functions (293). Furthermore, minor
alleles of CNR1 polymorphisms rs6928499, rs1535255, and
rs2023239 might be associated with a lower risk to develop
antipsychotic-induced metabolic syndrome. These relevant data
could result in potential pharmacogenetic applications to
optimize drug management of schizophrenic patients (294).
On the contrary, one study showed that G allele carriers of the
CNR1 rs1049353 (G1359A) polymorphism might be associated
with a poorer therapeutic response (233).
Gene and protein analysis of CB1r in peripheral blood cells
from schizophrenic patients attracted much attention. Peripheral
cell (e.g. lymphocytes) changes could be mirroring, at least in
part, some of the neuropathological hallmarks of the disorder. In
this regard, the first published study did not detect changes in the
CB1r mRNA levels in peripheral blood mononuclear cells
(PBMCs) between schizophrenia and control patients (295).
Similarly, no differences were observed in CB1r levels of
peripheral immune cells by flow cytometry between control
and schizophrenic patients, although a positive correlation
between CB1r expression on monocytes and cognitive
impairment was detected (296). However, an opposite result
revealed an increase of CB1r in PBMCs of schizophrenic patients
also evaluated by flow cytometry (297). Furthermore, there is an
increase of CB1r mRNA levels in PBMCs of schizophrenic
patients (298, 299) that may correlate with a reduced DNA
methylation of CNR1 promoter region (299). Moreover, CB1r
gene expression was correlated positively with positive and
negative syndrome scale (PANSS) total symptom severity and
negatively with cognitive functioning measures (298).Frontiers in Psychiatry | www.frontiersin.org 11Besides the extensive literature evaluating the role of CB1r in
schizophrenia, some efforts were done to complete the picture
regarding the involvement of eCBs and its degrading and
synthesizing enzymes as biomarkers. Leweke and cols reported
a significant increase of AEA levels in the CSF of schizophrenic
patients (300). In antipsychotic naïve first-episode paranoid
schizophrenic patients, there was an eightfold increase in AEA
levels in the CSF, whereas no alteration was present in patients
treated with typical but not atypical antipsychotics. Furthermore,
AEA levels were negatively correlated with psychotic symptoms
in nonmedicated acute schizophrenics (301). Similarly, blood
AEA levels were higher in patients with acute schizophrenia and
were normalized with the clinical remission (295). Increased
AEA levels were also detected in the CSF of schizophrenic
patients who used cannabis. Interestingly, the increase of AEA
was more than 10-fold higher in low-frequency compared with
high-frequency cannabis users (302). In addition, higher AEA
serum levels were obtained in twin-pairs discordant for
schizophrenia (303), or in schizophrenic patients with
substance use disorder (SUD) comorbidity, considering that
baseline AEA predicted endpoint SUD scores (304). However,
other studies showed different results such as no changes in
serum AEA levels (305), increased 2-AG and decreased AEA in
the cerebellum, Hipp, and PFC of schizophrenic patients (306).
With regard to degrading or synthesizing eCBs enzymes, the
relationship of some FAAH or NAPDE-PLD polymorphisms
with schizophrenia was studied, but no significant associations
were obtained (290, 307). In addition, FAAH and MAGL mRNA
levels were similar while FAAH activity was higher in the PFC of
schizophrenic patients compared to controls (273). Interestingly,
a reduction of FAAH mRNA levels correlated with clinical
remission in schizophrenic patients (295). Furthermore, in FEP
patients, some interesting correlations were detected between
peripheral FAAH and DAGL expression and short-term verbal
memory, NAPE-PLD expression and working memory, and
MAGL expression and attention. Accordingly, the authors
suggested the use of these ECS elements as biomarkers or
pharmacological targets for FEP (308). Finally, mRNA levels of
the 2-AG metabolizing enzyme, a-b-hydrolase domain 6
(ABHD6), were significantly increased in patients with
schizophrenia (309).
Notwithstanding the scarce literature exploring the role of
CB2r in schizophrenia, some important findings suggest its
involvement and draw attention to research on its therapeutic
potential. Perhaps, de Marchi and cols. published the first
evidence measuring CB2r mRNA levels by semi-quantitative
RT-PCR in PBMCs from schizophrenic patients in their acute
phase, and when clinical remission was achieved after
antipsychotic treatment with olanzapine. CB2r gene expression
significantly decreased in PBMCs from patients in clinical
remission (295). In FEP patients, CB2r protein expression was
significantly down-regulated together with reduced levels of
eCBs synthesizing enzymes (NAPE-PLD and DAGL) (310).
Interestingly, increased CB2r gene expression was found in
schizophrenic patients' PBMCs (298), correlating with PANSS
and cognitive performance severity (296, 298), and in cells of theApril 2020 | Volume 11 | Article 315
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cols. evaluated the implication of specific CNR2 polymorphisms
in schizophrenia. R63 allele of rs2501432 (R63Q), C allele of
rs12744386, and the haplotype of the R63-C allele were
significantly increased in patients with schizophrenia in
comparison with control subjects. Apparently, these
polymorphic alterations of CNR2 are associated with loss of
function. A lower response to CB2r ligands was found in
cultured CHO cells transfected with the R63 allele. Reduced
CB2r mRNA and protein expression levels were found in the
DLPFC of schizophrenic patients independently of the diagnosis
(265). In addition, the association between three CNR2
polymorphisms (rs2501432C/T, rs2229579C/T, rs2501401G/A),
and schizophrenia was explored (311). However, other CNR2
polymorphisms (rs6689530 and rs34570472) were not associated
with schizophrenia in a Korean population (289).
Bipolar Disorder
Bipolar disorder (BD) is a debilitating, lifelong neuropsychiatric
illness characterized by unsteady mood states alternating from
(hypo)mania to depression. According to the DSM-5, for a
diagnosis of BD it is necessary to meet specific criteria for a
manic episode that may be followed by hypomanic or major
depressive episodes (63). Despite the availability of effective
pharmacological agents, BD is inadequately treated in a subset
of patients, so the identification of new therapeutic targets is
necessary. In this sense, the close implication of ECS in mood
regulation suggested its involvement in BD (312). This
assumption is supported by the observation of the effects of
high doses of cannabis and THC in healthy patients, producing
psychosis, sometimes with marked hypomanic features (313). In
addition, THC and cannabidiol (CBD), the main components of
Cannabis sativa plant, may present mood stabilizing properties.
Therefore, there is an increasing interest to evaluate ECS
implication in BD.
First studies were focused on the evaluation of
polymorphisms of CNR1 gene in BD pathophysiology. One
study carried out in patients with BD within a Turkish
population investigated the implication of three types of
polymorphisms of CNR1 in this disease, demonstrating that
only one of them (rs6454674) could be correlated with BD. In
addition, the mean of the yearly maniac attacks was statistically
higher in patients presenting heterozygote rs6454674 T/G
polymorphisms compared to those with homozygote
polymorphism (314). In addition, the association of CNR1
rs1049353 (1359 G/A) and FAAH rs324420 SNP (cDNA 385C
to A) polymorphisms with BD was assessed in a Caucasian
population. Here, the authors concluded that the distribution of
CNR1 1359 G/A genotypes and alleles did not differ between BD
and healthy patients, whereas the frequency of the AC genotype
of FAAH (cDNA 385C to A) polymorphism was slightly higher
in BD patients (232).
Nevertheless, other studies did not identify differences in ECS
components between BD and healthy controls. Indeed, no
differences were obtained between BD patients and healthy
controls in DNA methylation of the CNR1 gene promotor
region (299). Furthermore, a polymorphism of CNR1Frontiers in Psychiatry | www.frontiersin.org 12promotor region was evaluated in another study, and no
changes were observed in BD patients, concluding that it was
not likely to relate with BD (315). Koethe and cols. carried out a
study with post-mortem brain samples from BD patients and
controls, evaluating numerical density of neurons and
immunopositive glial cells for CB1r. No changes were found in
these patients (223). Furthermore, in another study evaluating
polymorphisms of CNR1 and FAAH, no significant differences
or association were observed in BD patients (316).
Because of these contradictory results, some authors shifted
their attention to the implication of CB2r in BD, with limited but
promising findings. A genetic association was observed in
patients with BD and CNR2 rs41311993 (524C/A)
polymorphism, but not SNPs of rs2229572 (1073C/T) or
rs2501432 (315A/G), suggesting that CB2r may play a role in
BD (317). In addition, a genome-wide association study carried
out in a population from the UK biobank, identified the
association of a locus in CNR2 with distressing psychotic
experiences, providing support for a shared genetic liability
with BD and other neuropsychiatric disorders (318).
In summary, there is limited information about the
implication of ECS in the pathophysiology of BD. Thus, more
preclinical and clinical studies are needed to explore further its
role in the development of this neuropsychiatric disorder and its
usefulness as a therapeutic target to improve BD management.
Post-Traumatic Stress Disorder
Post-traumatic stress disorder (PTSD) is a chronic and disabling
mental disease caused by the exposure to stressful, frightening or
distressing events, and is included in the category of trauma- and
stressor-related disorders in the DSM-5 (63). PTSD patients
experience intrusion symptoms, persistent avoidance of any
stimuli associated with the traumatic event, negative alterations
in cognition and mood, and disturbances in arousal and
reactivity, that must last more than 1 month and produce
distress or functional impairment (63). The neurobiological
mechanisms underlying PTSD-related symptomatology are not
completely understood, being a limiting factor to identify new
therapeutic targets. In this regard, a relevant association between
ECS and PTSD was suggested providing interesting results about
the potential development of new pharmacological approaches.
Indeed, preclinical and clinical findings point out the
involvement of certa in ECS components in PTSD
symptomatology, such as CB1r or FAAH, suggesting its
potential role as biomarkers for PTSD (319, 320).
Animal Studies
The involvement of CB1r in PTSD is supported by the presence
of this receptor in brain areas regulating the response to stress
and to changes observed in different animal models of PTSD. For
instance, using a shock and reminder model of PTSD, higher
mRNA levels of CB1r were detected in the BLA (133), and
increased CB1r protein expression was found in the BLA and the
CA1 region of the Hipp (321) of exposed mice as well. On the
other hand, in a predator exposure-based PTSD model, anxiety-
like behavior was negatively correlated with CB1r gene
expression in the PFC and the amygdaloid complex, whereasApril 2020 | Volume 11 | Article 315
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and cols. reported in young Sprague-Dawley rats, that the
exposure to an unpredictable electric shock model of PTSD
induced a down-regulation of CB1r gene expression in
comparison with nonstressed rats. Interestingly, the authors
showed sex differences in the stress-related regulation of CB1r,
showing that females presented higher mRNA levels of CB1r, as
well as greater CB1r inactivation by phosphorylation. The
authors concluded that these sex-related differences could lead
to increased susceptibility to stress-related anxiety disorders,
including PTSD, in females (323). A genetic approach was
used to evaluate further the involvement of CB1r in the
regulation of stress response. Repeated exposure to an acoustic
stressor (high intensity bell sound) did not produce changes in
adrenocorticotropin hormone (ACTH) or corticosterone (CS)
levels in CB1−/− mice. These results suggested that the presence
of CB1r is essential in the regulation of the stress response, and
that CB1−/− mice may result appropriate to model some forms of
PTSD (324).
Pharmacological manipulation approaches of the CB1r were
also explored in several rodent models of PTSD and its potential
usefulness as a therapeutic biomarker. The blockade of CB1r
with rimonabant increased freezing behavior in a PTSD model of
shock and reminder during cued expression/extinction training
(325). On the other hand, several authors evaluated the effects of
cannabinoid activation by WIN-55,212-2 administration into
hippocampal CA1 region. The results showed a normalization of
shock-induced upregulation of CB1r in the PFC and CA1 region
of the Hipp (321, 326) and facilitation of inhibitory avoidance
extinction in a fear-related inhibitory avoidance paradigm (327).
All these effects were blocked by AM251 administration.
Furthermore, WIN-55,212 administration into the BLA
normalized stress-induced effects on inhibitory avoidance and
acoustic startle response and facilitated fear extinction in a single
prolonged stress (SPS) model of PTSD. These effects were
blocked by AM251 (321, 328, 329). Similarly, the injection of
WIN-55,212 in the NAc of rats exposed to a shock and reminder
model of PTSD significantly facilitated the fear extinction
process (330). Interestingly, Goodman and Packard
demonstrated that systemic or intradorsolateral striatum (DLS)
administration of WIN-55,212 could impair the consolidation of
stimulus–response memory, suggesting relevant consequences
for neuropsychiatric disorders such as PTSD (331). However, the
intra-PFC administration of WIN-55,212 did not modulate fear
extinction disturbances induced by the exposure to the SPS
model (329). Finally, according to the results obtained with
WIN-55,212, Reich and cols. studied the effects of a CB1r
selective agonist, ACEA, in rats exposed to 3 weeks of a
chronic-mild-unpredictable protocol followed by fear
conditioning evaluation. In this study, ACEA administration
significantly reduced freezing behavior in stressed rats,
enhancing long-term extinction of fear-related memories (332).
In order to validate that cannabinoid activation improves
disturbances induced by stress- or trauma-related stimuli, the
effects of pharmacological endocannabinoid signaling facilitation
were analyzed. In a fear conditioning paradigm, theFrontiers in Psychiatry | www.frontiersin.org 13administration of AM404 led to a dose-dependent
enhancement in fear extinction, as well as a decreased shock-
induced reinstatement of fear. Interestingly, the administration
of rimonabant together with AM404 reversed the improvement
of extinction, suggesting that AM404 effects were related to an
increase in CB1r activation during extinction training (333). In
addition, the injection of the FAAH inhibitor, URB597,
normalized the upregulation of CB1r in the CA1 of Hipp and
BLA of rats exposed to a shock and reminder model of PTSD
(334) and attenuated startle response and anxiety-like behavior
in a predator exposure animal model of PTSD (335).
Interestingly, these effects were abolished by CB1r blockade,
suggesting the implication of CB1r on URB597 effects (335,
335). Similar results were obtained with the administration of
URB597 into CA1 (Hipp) and BLA brain regions, showing a
facilitation of extinction processes and attenuation of startle
response, anxiety- and depression-like behaviors mediated by
CB1r activation (133, 336, 337). Furthermore, URB597
administration additionally prevented the increase of CB1r
levels in CA1 and BLA after rodent exposure to shock and
reminder model of PTSD (321).
FAAH inhibition significantly facilitates CB1r-mediated
signaling of AEA and can produce a greater beneficial
spectrum of biological effects than those caused by direct CB1r
activation. Interestingly, the role of FAAH in learning and
memory was evaluated by using another FAAH inhibitor, OL-
135. The administration of this drug increased acquisition and
extinction rates in mice exposed to fixed platform water maze
test. Rimonabant blocked OL-135-induced effects on both
acquisition and extinction levels (338). In the same study, the
authors revealed that FAAH−/− mice phenotype was similar to
that obtained after OL-135 administration, suggesting that the
increase in AEA levels facilitates extinction processes, and that
CB1r would be critically involved (338). FAAH inhibition and
the consequent increase of AEA in the brain regions involved in
the regulation of stress and anxiety seem to restore dysfunctional
homeostasis of AEA signaling because of stress exposure. Thus,
FAAH must be strongly considered as a target for PTSD
management (139).
Human Studies
According to the involvement of ECS components in several
behavioral traits of PTSD in animal models, various studies
explored alterations in different biological samples (post-
mortem brain tissue, blood, hair) collected from PTSD patients
and adequately paired controls. At the peripheral level, some
authors studied the possible correlation between CNR1
polymorphisms and PTSD symptoms. The rs1049353
polymorphism of CNR1 was studied in PTSD patients to
correlate specific alleles or genotypes with fear and/or
dysphoric symptoms of PTSD. This study suggested that
rs1049353 polymorphism interacts with childhood physical
abuse to increase fear but not dysphoric symptoms in PTSD
(339). In another study carried out in a Caucasian population,
the association between variants of CNR1 gene haplotypes and
diagnosis of PTSD was studied. The authors reported that theApril 2020 | Volume 11 | Article 315
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PTSD controls, and the variant C-G was less common in PTSD
compared to non-PTSD patients (340).
A different approach was the measurement of plasmatic eCBs
in a selected cohort of patients that suffer the terroristic attacks of
the World Trade Center in 2001 and met the diagnostic criteria
for PTSD. 2-AG, AEA, and cortisol concentrations were
measured. Only 2-AG was significantly reduced in PTSD
patients, while no significant differences were found in AEA or
cortisol concentrations (341). Another study showed reduced
AEA and cortisol concentrations in PTSD patients compared to
healthy controls with lifetime clinical histories of trauma (342).
Despite these contradictory results, the fluctuations in plasmatic
concentrations of eCBs may affect the reproducibility of the
evaluation. Thus, the assessment of eCBs alterations in hair
samples provides a more stable measurement. Hair
concentrations of PEA (palmitoylethanolamide), OEA
(oleoylethanolamide) and SEA (steraoylethanolamide) were
measured in war survivors with and without PTSD. A
regression analysis revealed a strong negative relationship
between these endocannabinoids and the severity of PTSD
symptoms. OEA concentrations were significantly reduced in
hair samples from PTSD patients (343).
Only one human study analyzed CB1r binding using the
CB1r-selective radioligand [11C]OMAR by PET. Results
showed elevated CB1r binding values, especially in women,
together with lower AEA and cortisol in PTSD patients. The
authors suggested that abnormal CB1r-mediated AEA signaling is
involved in the etiology of PTSD (342). In addition, fMRI was also
used to evaluate FAAH implication in PTSD symptomatology. A
common SNP (C385A) in the human FAAH gene was correlated
with the quicker habituation of amygdala reactivity to threat and
lower score on stress-reactivity. This variant reduced FAAH
activity and possibly increased AEA-induced endocannabinoid
signaling (344–346). Furthermore, Rabinak and cols. conducted
an fMRI study with healthy volunteers and patients receiving
acute dronabinol (synthetic THC) oral administration in a
standard Pavlovian fear extinction paradigm. Interestingly,
dronabinol enhanced extinction learning, providing the first
evidence about the feasibility of pharmacological enhancement
of extinction learning in humans using cannabinoid system
modulators (347, 348). Some clinical trials with PTSD patients
suggested the usefulness of dronabinol for improving the global
PTSD symptom severity, sleep quality, frequency of nightmares,
and PTSD hyperarousal symptoms (349). Similar results were
obtained with nabilone, since its administration to PTSD patients
improved insomnia, PTSD symptoms, and global assessment of
functioning, reducing the frequency and intensity of nightmares
(350, 351). Nevertheless, more randomized and controlled clinical
trials are needed to confirm dronabinol or nabilone potential
therapeutic application in the management of PTSD.
Attention-Deficit/Hyperactivity Disorder
ADHD is a neuropsychiatric disorder characterized by persistent
pattern of inattention and/or hyperactivity-impulsivity that
interferes or reduces the quality of social, academic, or
occupational functioning in accordance with DSM-5 (63). InFrontiers in Psychiatry | www.frontiersin.org 14the last years, the identification of different components of the
ECS that are potentially involved in ADHD pathophysiological
mechanisms has attracted much attention as shown below.
Animal Studies
An experiment carried out in SHR rats (an animal model
reproducing some features of ADHD) evaluated the modulating
effects of the cannabinoid system on impulsivity, using a delay
reinforcement task and the administration of WIN55212-2 or
AM251 (352). This study concluded that treatment with
WIN55212-2 decreased whereas AM251 increased the choices
of the large reward, suggesting that CB1r plays a relevant role in
impulsive behavior. Furthermore, basal gene and protein
expression of CB1r in the brainstem of SHR rats was
significantly lower in comparison with their normotensive
counterpart, Wistar rats (353). Moreover, the overexpression of
four genes, between them CNR1, was strongly associated with
overall poor performance on mice during their gestational growth
because of a malnutrition via high-fat or low-protein diets on the
dam (354). These abnormal disturbances on diet in the gestational
period are linked to the etiology of multiple neurodevelopmental
disorders, including ADHD (355).
The psychostimulant drug amphetamine is often prescribed
to treat ADHD. The administration of amphetamine increases
monoamine neurotransmission in the brain regions as NAc and
medial PFC. Accumulating reports supported the role of CB1r in
the regulation of monoamine release, suggesting its possible
involvement in ADHD. The administration of rimonabant did
not affect monoamine release whereas dose-dependently
abolished amphetamine-induced dopamine release in the NAc.
This result suggested that CB1r is essential to reach the
therapeutic effect of amphetamine, mediated at least in part, by
the enhancement of dopaminergic signaling in the mesolimbic
system in the NAc (356).
Human Studies
As previously stated, there is large available evidence regarding
the role of different variants of CNR1 gene in psychiatry. In
relation to ADHD, SNP variants at the CNR1 gene were tested
on a family-based sample of trios (an ADHD child and their
parents) and on an unselected adolescent sample from Northern
Finland. The study detected a significant association of a SNP
haplotype (C-G) with ADHD suggesting a greater risk in males
than females (340). Another study reported the interaction of the
two most studied CNR1 polymorphisms, rs806379 and
rs1049353, that are involved with early psychosocial adversity
(357). These polymorphisms of the CB1 receptor are highly
associated with impulsivity representing an usual phenotype
involved in ADHD (358).
Eating Disorders
The most common eating disorders are anorexia nervosa (AN)
and bulimia nervosa (BN). According to DSM-5, AN is
characterized by distorted body image and excessive dieting
leading to severe weight loss with a pathological fear of
becoming fat, whereas BN is characterized by recurrent
episodes of binge eating alternated with recurrentApril 2020 | Volume 11 | Article 315
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(63). Importantly, ECS plays a major regulatory role on feeding
behaviors and energy balance (359) that has drawn attention to
its relationship with ADHD neurobiology. This can be confirmed
by rodents with diet-induced or genetic obesity promoting an
increase of endocannabinoid hypothalamic levels (360).
Animal Studies
The participation of CB1r in the regulation of feeding behavior is
well established. The acute administration of rimonabant
decreased food intake and body weight gain and reduced CB1r
gene expression in the PVN of male Wistar rats. However, a
chronic treatment led to tolerance to the hypophagic effects of
CB1r blockade without changes in food intake, body weight, or
hypothalamic mRNA gene expression (361). Another study on
rimonabant-treated male Sprague-Dawley rats showed that the
colocalized Fos labeling of hypothalamic regions with
anorexigenic and orexigenic peptides had decreased
neuropeptide Y (NPY) levels (362). More recently, another
study was performed in CB1r conditional and CB2−/− mice.
The hypothalamic neuropeptide expression pattern displayed a
marked decrease of proopiomelanocortin (POMC) and cocaine-
amphetamine-regulated transcript (CART) expression in the
arcuate nucleus of the hypothalamus (ARC), both
neuropeptides involved on anorexigenic and behavioral
changes in food intake (363).
C57BL/6J mice were treated with naltrexone (opioid receptor
antagonist), rimonabant, and BD-1063 (sigma-1 receptor
antagonist) on an intermittent maladaptive feeding animal
model. All the treatments reduced overconsumption of a
palatable food (364). In addition, the administration of other
cannabinoid compounds such as CBD or CB1r antagonists
significantly reduced food intake and body weight gain (365–
368). Recently, a study based on the activity-based anorexia
(ABA) model reproducing key aspects of human AN, measured
levels of AEA, 2-AG, and the CB1r in different brain regions of
female ABA Sprague-Dawley rats. 2-AG significantly decreased
in various brain areas but not in the caudate putamen, whereas
no changes were observed in AEA. Density of CB1r was reduced
in the dentate gyrus of Hipp and in the lateral Hyp (369). These
results suggested that ECS is involved in the contribution and
maintenance of some aspects in the pathophysiology of AN.
Human Studies
Although there is some progress in the understanding of the
mechanisms underlying eating disorders and body weight
regulation, there is still lack of information to suggest
cannabinoid related treatment for patients with AN and BN.
However, some studies suggest that the ECS, primarily CB1r,
plays a key role in the reward areas and metabolic patterns
involved in food intake and weight gain. In this regard, a PET
study on 54 patients with food intake disorders (FID, including
AN and BN) revealed an inverse association between regional
CB1r availability and body mass index (BMI) in the Hyp and
brainstem areas in both patients with FID and healthy individuals.
However, FID patients negatively correlated with BMI throughoutFrontiers in Psychiatry | www.frontiersin.org 15the mesolimbic reward system (370). Also, global CB1r availability
is significantly increased in the cortical and subcortical brain areas
in AN patients compared with healthy controls, maybe due to a
compensatory mechanism of an underactive ECS in these patients
(371). Finally, eating disorder female patients presented lower
CB1r mRNA levels in PBMCs (372).CONCLUSIONS
The close involvement of the ECS in the etiology and
neuropathology of neuropsychiatric disorders is undeniable.
Considering the urgent need to identify new and better
biomarkers in psychiatry, the evidence included in this review
provides an overview of the opportunities that cannabinoid
receptors (Table 1), endogenous cannabinoid ligands (Table 2),
or their metabolizing enzymes (Table 3) offer as potential
biomarkers in the clinical setting. The large number of
pharmacological studies with various cannabinoid compounds,
mainly conducted in animal models, reported interesting and
promising information to design new therapeutic strategies that,
alone or in combination with the drugs currently used in psychiatry,
may improve the efficacy and safety of psychiatric
disorders treatment.
According to the information gathered in the present review
from pharmacological and genetic approaches mainly performed in
rodents, some general conclusions can be drawn regarding the
usefulness of ECS components as therapeutic biomarkers (Figure
2). The blockade or genetic deletion of CB1r is closely associated
with the worsening of emotional behavioral traits, as revealed
principally in animal models of anxiety, depression or PTSD,
whereas CB1r pharmacological activation induces an
improvement effect. On the other hand, CB1r activation induces
psychotic symptoms, while CB1r blockade presents antipsychotic
effects. Regarding CB2r, its pharmacological activation or its
overexpression by means of genetic manipulation or chronic
treatment induced upregulation improving anxiety- and
depressive-like behaviors, as well as schizophrenia-like traits. In
contrast, all these behaviors worsen by CB2r blockade or gene
deletion. Interestingly, the strengthening of the endocannabinoid
tone, by the inhibition of enzymatic degradation or the blockade of
reuptake mechanisms, is closely related with an improvement,
particularly in emotional regulation as explored in animal models
of anxiety, depression, and PTSD.
Therefore, the available evidence points out that the
functional manipulation of the ECS components presents a
great therapeutic potential. However, the close interaction of
the ECS with other neurotransmitter or neurohormonal systems,
as well as the specific and differential neuroanatomical
distribution of the ECS components, provides a complex
scenario not only from a therapeutic point of view but also
considering the occurrence of side effects. In this sense, some
aspects should be critically addressed, especially from a
pharmacological perspective. The dosing, duration, and
mechanism of action involved in the manipulation of the ECS
are crucial to reach an improvement and limit adverse reactions.April 2020 | Volume 11 | Article 315
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CB1r
Subjects/Diagnosis Sample/Intervention Method Measurement Results References
Healthy controls THC (10 mg) p.o. [11C]MePPEP PET CB1r availability in amygdala ↑ CB1r Bhattacharyya
et al. (166)




Anxiety level ↑ anxiety Bergamaschi
et al. (168)






DD PMBT – anterior
cingulate cortex
Immunohistochemistry Density of CB1r
immunopositive glial cells
↓ CB1r Koethe et al.
(223)




CB1r relative gene expression ↑ CB1r Choi et al.
(224)




DD/SCZ Blood DNA Genotyping CNR1 rs1049353 (1359 G/A)
polymorphism




DD Blood DNA Genotyping CNR1 rs1049353 (1359 G/A)
polymorphism




DD Blood DNA Genotyping CNR1 rs1049353 (1359 G/A)
polymorphism







Blood DNA Genotyping CNR1 rs1049353 (1359 G/A)
polymorphism
↓ risk for anhedonia/DD in A-




DD in Parkinson's disease Blood DNA Genotyping CNR1 (AAT)n triplet
polymorphism






Blood DNA Genotyping CNR1 rs2023239
polymorphism
↓ risk for DD in C-allele carriers Icick et al.
(239)




CB1r binding ↑ CB1r Dean et al.
(269)




CB1r binding ↑ CB1r Jenko et al.
(270)




CB1r binding ↑ CB1r Volk et al.
(271)




CB1r binding ↑ CB1r Zavitsanou
et al. (274)




CB1r binding ↑ CB1r Newell et al.
(275)










SCZ PMBT – prefrontal
cortex
Western Blot CB1r protein ↓ CB1r








CB1r relative gene expression ↓ CB1r Muguruzaf
et al. (273)
SCZ In vivo neuroimaging
(several brain regions)
[11C]-OMAR PET CB1r binding ↑ CB1r (only in the pons) Wong et al.
(279)
SCZ In vivo neuroimaging
(several brain regions)
[18F]-MK-9470 PET CB1r binding ↑ CB1r Ceccarini et al.
(280)
SCZ In vivo neuroimaging
(several brain regions)
[11C]-OMAR PET CB1r binding ↓ CB1r Ranganathan
et al. (281)




CB1r binding ↓ CB1r ↔ severity Borgan et al.
(283)
SCZ Blood DNA genotyping CNR1 rs1049353,
rs7766029, rs806366
polymorphisms
Nominal association Costa et al.
(290)
SCZ Blood DNA genotyping CNR1 (AAT)n triplet
polymorphism
9 and 17 repeat alleles ↔
↑ susceptibility disorganized SCZ
Ujike et al.
(285)
SCZ Blood DNA genotyping CNR1 rs1049353 (1359 G/A)
polymorphism




SCZ Blood DNA genotyping CNR1 rs2023239
polymorphism
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CB1r
Subjects/Diagnosis Sample/Intervention Method Measurement Results References
FEP Blood DNA genotyping CNR1 rs7766029,
rs12720071 polymorphisms
↑ better improvement in




SCZ Blood DNA genotyping CNR1 rs6928499,
rs1535255, rs2023239
polymorphisms
↓ risk metabolic syndrome in
minor alleles carriers
Yu et al. (294)




SCZ Blood – PBMCs Flow cytometry CNR1 rs1049353 (1359 G/A)
polymorphism
↑ CB1r De Campos-
Carli et al.
(297)
SCZ Blood - PBMCs Quantitative polymerase
chain reaction (qPCR)
CB1r expression ↑ CB1r Chase et al.
(298)
BD Blood DNA genotyping CNR1 rs6454674
polymorphism




Blood DNA genotyping CNR1 rs1049353
polymorphism
↑ risk for PTSD-related




PTSD In vivo neuroimaging
(several brain regions)
[11C]-OMAR PET CB1r binding ↑ CB1r Neumeister, A.
et al. (342)
ADHD Blood DNA genotyping SNP variants at the CNR1
gene
↑ frequency SNP haplotype (C-
G)
Lu et al. (340)
ADHD
(alcoholic patients)
Blood DNA genotyping CNR1 (AAT)n triplet
polymorphism
↑ frequency longer form of alleles Ponce et al.
(358)
AN/BN In vivo neuroimaging
(several brain regions)
[18F]-MK-9470 PET CB1r binding ↑ CB1r Gérard et al.
(371)
AN/BN Blood Quantitative polymerase
chain reaction (qPCR)





Subjects/Diagnosis Sample Method Measurement Results References
General population Buccal mucosa DNA genotyping CNR2 rs2501432 (R63Q)
polymorphism
↑ risk for AD/DD in rs2501432 R-




DD Blood DNA genotyping CNR2 rs2501431
polymorphism




DD Blood DNA genotyping CNR2 rs2501432 (R63Q)
polymorphism
↑ frequency R63Q polymorphism Onaivi et al.
(249, 241)
SCZ Blood – PBMCs Quantitative polymerase
chain reaction (qPCR)
CB2r relative gene expression ↓ CB2r with clinical remission De Marchi
et al. (295)
SCZ Blood – PBMCs Quantitative polymerase
chain reaction (qPCR)
CB2r relative gene expression ↑ CB2r Chase et al.
(298)
SCZ Blood – PBMCs Flow cytometry CB2r expression ↑ CB2r De Campos-
Carli et al.
(297)
SCZ Blood – PBMCs Western Blot CB2r expression ↓ CB2r Bioque et al.
(310)
SCZ Blood DNA genotyping CNR2 rs2501432 (R63Q),
rs12744386 polymorphism
↑ frequency in rs2501432 R63
and rs12744386 C alleles
Ishiguro et al.
(265)
SCZ Blood DNA genotyping CNR2 rs2501432C/T
polymorphism
↑ risk for SCZ in T-allele carriers Tong et al.
(311)
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hyperactivity disorder; AN, anorexia nervosa; BN, bulimia nervosa; PMBT, post-mortem brain tissue; PET, positron emission tomography; PBMCs, peripheral blood mononuclear cells.
↓: decrease and ↑: increase.1 | Article 315
Navarrete et al. Endocannabinoid System Biomarkers in PsychiatryTABLE 3 | Main findings from human studies supporting the role of FAAH as a biomarker in psychiatric disorders.
FAAH
Subjects/Diagnosis Sample Method Measurement Results References
Healthy controls Blood DNA Genotyping FAAH rs324420 (C385A)
polymorphism




PING study participants Saliva DNA Genotyping FAAH rs324420 (C385A)
polymorphism






Blood DNA Genotyping FAAH rs324420 (C385A) & CRFR1
minor alleles polymorphisms
↑ anxiety level in FAAH A-allele and





Saliva DNA Genotyping FAAH rs324420 (C385A) and
CRHR1 rs110402 polymorphisms






DNA Genotyping FAAH rs324420 (C385A)
polymorphism






DNA Genotyping FAAH rs324420 (C385A)
polymorphism




DD/BD Blood DNA Genotyping FAAH rs324420 (C385A)
polymorphism







FAAH activity ↑ FAAH activity Muguruza
et al. (273)
SCZ Blood Quantitative polymerase
chain reaction (qPCR)
FAAH relative gene expression ↓ FAAH with clinical remission De Marchi
et al. (295)
BD Blood DNA Genotyping FAAH rs324420 (C385A)
polymorphism
↑ frequency AC genotype carriers Monteleone
et al. (232)Frontiers in Psychiatry | www.frontiersin.org 18 April 2020 | Volume 11AD, anxiety disorder; DD, depressive disorder; SCZ, schizophrenia; BD, bipolar disorder; PMBT, post-mortem brain tissue; FAAH, fatty acid amido hydrolase.




Sample Method Measurement Results References




↑ AEA in minor depression
↓ 2-AG in major depression
Hill et al. (226)






Hill et al. (227)
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Navarrete et al. Endocannabinoid System Biomarkers in PsychiatryApart from the widely explored role of CB1r, it should be noted
that in recent years an increasing emphasis is being placed on the
design of strategies to regulate endogenous cannabinoid tone,
through inhibitors of the degradation or reuptake of eCBs. Since
this approach provided negative results, particularly regarding
the inhibition of FAAH (373), current trends focused on the
combination of different mechanisms of action to enhance the
endocannabinoid tone (374). Moreover, the pharmacological
modulation of CB2r has also attracted much attention given its
safety profile and the wide range of properties attributed to it,
including mood and cognitive regulation. Thus, future priorities
for both human and animal research would be the potentiation
of both endocannabinoid tone and CB2r-mediated actions.
The trials carried out on patients show alterations of the ECS
components at different levels, which in certain cases are related
to risk or predictive factors regarding the evolution of the disease,
or the degree of response to drug treatment. It is relevant to
highlight the underlying sex-dependent effects in terms of sexual
dimorphism of the ECS (375) and sex differences in prevalence
rates and presentation of the psychiatric disorders (376). These
could be involved not only in the changes of the ECS components
to provide sex-related diagnostic or prognostic biomarkers, but
also in the pharmacological actions derived from the treatment
with cannabinoid compounds (377). Finally, it is important to
note that more in vivo clinical studies are recently being carried
out employing blood samples (PBMCs, plasma) or neuroimaging
techniques (PET, fMRI) to identify ECS-related alterations,
providing very relevant data. In this sense, a higher effort isFrontiers in Psychiatry | www.frontiersin.org 19required to design and perform more clinical studies, especially
increasing the sample sizes to achieve greater significance,
representativeness and reproducibility, finally making possible
to identify some of the ECS components as useful biomarkers
applicable to clinical practice in psychiatry.AUTHOR CONTRIBUTIONS
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